文献速递肺栓塞与肺血管病

GDF-15可提高肺动脉高压风险分层的预后准确性

Growth Differentiation Factor-15 Improves Prognostic Accuracy of Risk Stratification in Pulmonary Arterial Hypertension.
PubMed 文献 · Chest · 2025-11-04

本研究基于中国国家罕见病注册系统开展全国多中心回顾性研究,纳入435例肺动脉高压患者(发现队列218例,验证队列217例),检测血清GDF-15水平并比较现有风险模型加入GDF-15后的预测能力。结果显示GDF-15升高与死亡风险增加独立相关,基于COMPERA构建的含GDF-15新模型C-index在发现队列由0.743升至0.767,验证队列由0.658升至0.687。

要点

  • 血清GDF-15升高与PAH患者全因死亡风险增加独立相关。
  • 在COMPERA风险模型基础上加入GDF-15可提升死亡预测区分度。
  • GDF-15有望作为现有PAH风险评估策略的附加预后生物标志物。

核心结论

  • GDF-15可能改善现有肺动脉高压风险评估策略对全因死亡的预测效果。

研究设计与样本

  • 全国多中心回顾性研究,从中国国家罕见病注册系统纳入435例PAH患者,发现队列218例、验证队列217例。
  • 采集血清样本测定GDF-15水平,入组后完成右心导管检查、WHO功能分级等综合评估。
  • 采用C-index比较多个现有风险模型加入GDF-15前后的预测能力,重点为COMPERA模型。

主要发现

  • 发现队列中GDF-15升高与死亡风险增加显著相关,单变量Cox分析HR为1.658(95%CI 1.099-2.499;P=.016),完全校正后HR为1.678(95%CI 1.018-2.765;P=.042)。
  • 验证队列中对应HR分别为1.982(95%CI 1.169-3.361;P=.011)和1.817(95%CI 1.035-3.190;P=.038)。
  • 基于COMPERA构建的含GDF-15新风险模型对死亡预测区分度提高,发现队列C-index由0.743升至0.767,验证队列由0.658升至0.687,拟合度增强。

临床怎么用

  • 在现有PAH风险评估(如COMPERA)基础上,可考虑检测血清GDF-15以辅助细化死亡风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The etiology of pulmonary arterial hypertension (PAH) is complex and the risk is heterogeneous. Growth differentiation factor-15 (GDF-15) has been reported to be associated with the prognosis of patients with PAH, but whether the use of GDF-15 as an additional prognostic biomarker can improve preexisting PAH risk stratification remains unclear. RESEARCH QUESTION: Can the addition of GDF-15 improve the performance of existing prediction models for PAH? STUDY DESIGN AND METHODS: We conducted a nationwide, multicenter retrospective study in which 435 patients with PAH (218 in the discovery cohort and 217 in the validation cohort) were enrolled from the National Rare Diseases Registry System of China. Serum samples were collected and serum GDF-15 levels were determined. Comprehensive PAH assessments were conducted postenrollment, including right heart catheterization, World Health Organization functional class, and other relevant clinical indicators. C-indexes were used to compare the prediction power of several existing risk models with or without GDF-15 as a predictive biomarker, especially Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). RESULTS: In the discovery cohort, elevated levels of GDF-15 were significantly associated with an increased risk of mortality, with hazard ratios of 1.658 (95% CI, 1.099-2.499; P = .016) in univariate Cox analysis and 1.678 (95% CI, 1.018-2.765; P = .042) after full adjustment. The corresponding hazard ratios in the validation cohort were 1.982 (95% CI, 1.169-3.361; P = .011) and 1.817 (95% CI, 1.035-3.190; P = .038), respectively. A novel risk model incorporating GDF-15 was developed based on COMPERA, which demonstrated improved discrimination for mortality prediction and enhanced fit, with an increase in C-index from 0.743 to 0.767 in the discovery cohort and from 0.658 to 0.687 in the validation cohort. INTERPRETATION: Our results show that GDF-15 may improve the predictive effects of existing PAH risk assessment strategies on all-cause mortality.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Wang AY, Ma JL, Cui Y, et al. Growth Differentiation Factor-15 Improves Prognostic Accuracy of Risk Stratification in Pulmonary Arterial Hypertension. Chest. 2025. PMID: 41197865. doi:10.1016/j.chest.2025.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。